{"entity":{"id":"marginal-zone-lymphoma","kind":"cancer","name":"Marginal zone lymphoma","aka":["MZL","MALT lymphoma","Extranodal marginal zone lymphoma","Splenic marginal zone lymphoma","Nodal marginal zone lymphoma"],"tldr":"Marginal zone lymphoma is a slow B-cell lymphoma that often grows where the body has been fighting a chronic infection: the stomach with Helicobacter pylori, the eye, the skin or the spleen. Curing the infection cures many early cases; the rest are treated with rituximab, chemotherapy or BTK inhibitors.","summary":"Marginal zone lymphomas come in three forms. Extranodal (MALT) lymphoma arises in mucosal tissue chronically stimulated by infection or autoimmunity: gastric MALT lymphoma from Helicobacter pylori, ocular adnexal from Chlamydia in some regions, salivary gland in Sjogren's syndrome and thyroid in Hashimoto's disease; eradicating H. pylori puts most early gastric cases into remission, and localised disease elsewhere is cured with low-dose radiotherapy. Splenic marginal zone lymphoma presents with a large spleen and circulating villous lymphocytes and is linked to hepatitis C, whose treatment can induce remission; rituximab has replaced splenectomy. Nodal marginal zone lymphoma behaves like follicular lymphoma. Systemic treatment when needed is rituximab alone or with bendamustine or chlorambucil, lenalidomide-rituximab, and the BTK inhibitors ibrutinib and zanubrutinib for relapsed disease.","asOf":"2026-09-17","wikipedia":"https://en.wikipedia.org/wiki/Marginal_zone_B-cell_lymphoma","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Marginal_zone_B-cell_lymphoma"},{"label":"Lymphoma Action: helpline services","url":"https://lymphoma-action.org.uk/information-and-support/support-you/helpline-services"},{"label":"Lymphoma Action: questions to ask your medical team about lymphoma","url":"https://lymphoma-action.org.uk/information-and-support/tests-scans-and-lymphoma-staging/questions-ask-your-medical-team-about-lymphoma"},{"label":"Lymphoma Action: follow-up after lymphoma treatment","url":"https://lymphoma-action.org.uk/information-and-support/living-and-beyond-lymphoma/follow-after-lymphoma-treatment"},{"label":"Lymphoma Action: infections, risk and prevention","url":"https://lymphoma-action.org.uk/information-and-support/side-effects-lymphoma-and-treatment/infections-risk-and-prevention"},{"label":"Lymphoma Action: neutropenia (low neutrophils)","url":"https://lymphoma-action.org.uk/information-and-support/side-effects-lymphoma-and-treatment/neutropenia-low-neutrophils"},{"label":"Lymphoma Action: cancer-related fatigue","url":"https://lymphoma-action.org.uk/information-and-support/side-effects-lymphoma-and-treatment/cancer-related-fatigue"},{"label":"Lymphoma Action: lymphoma, work and you","url":"https://lymphoma-action.org.uk/information-and-support/living-and-beyond-lymphoma/day-day-living/lymphoma-work-and-you"},{"label":"Maggie's: support and information","url":"https://www.maggies.org/support-and-information/"},{"label":"Lymphoma Action: active monitoring (watch and wait)","url":"https://lymphoma-action.org.uk/information-and-support/lymphoma-treatment/active-monitoring-watch-and-wait"},{"label":"Lymphoma Action: the emotional impact of living with lymphoma","url":"https://lymphoma-action.org.uk/information-and-support/living-and-beyond-lymphoma/emotional-impact-living-lymphoma"},{"label":"Macmillan: non-Hodgkin lymphoma","url":"https://www.macmillan.org.uk/cancer-information-and-support/lymphoma/non-hodgkin-lymphoma"}],"tags":["subtype-page"],"related":["follicular-lymphoma","waldenstrom","mantle-cell-lymphoma","dlbcl","ig-tcr-clonality","myd88-l265p","lymphoma-roadmap","lymphoma-ev-fixed-duration-chemotherapy-free-first-line"],"cancers":[],"sections":[],"technologies":["palliative-care","psycho-oncology","peer-support-groups","survivorship-care-plan","fertility-preservation","financial-navigation","cbt-fatigue-distress","exercise-during-chemotherapy","multidisciplinary-tumour-board","oncology-nutrition","prehabilitation","clonality-testing","cytogenetics-fish","flow-cytometry-mrd"],"targets":["malt1","bcl10","tnfaip3","notch2","klf2","birc3","cd20","myd88"],"drugs":["zanubrutinib","chlorambucil","lisocabtagene-maraleucel"],"companies":[],"institutions":[],"pathways":["inflammation-nfkb","notch","microbiome-tumour"],"terms":["myd88-l265p","ss18-ssx-fusion","lymphoma-tx-h-pylori-eradication","lymphoma-tx-watch-and-wait","lymphoma-tx-radiotherapy","cancer-related-fatigue","late-effects","febrile-neutropenia","neutropenia","financial-toxicity","central-venous-access","hypogammaglobulinaemia","performance-status","quality-of-life","lymphoma-decision-watch-and-wait","lymphoma-decision-trial","lymphoma-living-indolent-lymphoma","lymphoma-living-scanxiety-and-surveillance","lymphoma-living-infection-years-after","lymphoma-living-fatigue","watchful-waiting","lymphoma-bio-lymphgen","lymphoma-bio-transformation"],"trials":["augment","zuma-5","ielsg-19","mosun-len-mzl"],"people":[],"bottlenecks":[],"keyPapers":["paper-wotherspoon-h-pylori-malt-lancet-1993","paper-esmo-marginal-zone-lymphoma-zucca-ann-oncol-2020","paper-magnolia-zanubrutinib-mzl-ccr-2021","paper-augment-lenalidomide-rituximab-leonard-jco-2019"],"journals":[],"dependsOn":[],"notes":["Living with marginal zone lymphoma: This is orientation from public patient pages, guidelines and the trials themselves, not advice for your case: your own team's instructions and the 24-hour number they gave you come first, and no figure here is a prediction about you. The decision records, the question sets, the first 60 days checklist and the red cards on this page were written from the NHS, Lymphoma Action, Macmillan and Cancer Research UK patient pages, from NICE NG52, NG47, CG151 and NG234, from the NHS Breast Screening Programme protocols and the Green Book, and from the trial reports named beside each figure, all read on 1 October 2026."],"group":"haematologic","burden":"About one in ten non-Hodgkin lymphomas, the second commonest indolent type after follicular lymphoma; most patients live for many years and many are cured by treating the infection or inflammation that drove the disease.","subtypes":["Extranodal marginal zone lymphoma of MALT (gastric, ocular adnexal, salivary, thyroid, lung, skin)","Splenic marginal zone lymphoma","Nodal marginal zone lymphoma","Paediatric nodal marginal zone lymphoma (indolent)"],"biomarkers":["Helicobacter pylori status (gastric MALT)","t(11;18) MALT1 translocation (predicts failure of eradication therapy)","Hepatitis C serology (splenic)","MYD88 wild-type (distinguishes from Waldenstrom)","Plasmacytic differentiation and paraprotein"],"standardOfCare":[{"setting":"Gastric MALT lymphoma, H. pylori-positive","approach":"Eradication therapy and endoscopic follow-up; radiotherapy if the lymphoma persists or carries t(11;18).","refs":["non-hodgkin-lymphoma"]},{"setting":"Localised extranodal disease","approach":"Low-dose involved-site radiotherapy (as little as 4 Gy in two fractions for some sites); surgery rarely.","refs":["imrt-igrt","hypofractionated-radiotherapy"]},{"setting":"Splenic marginal zone lymphoma","approach":"Watch and wait if asymptomatic; antiviral therapy if hepatitis C-positive; rituximab alone or with chemotherapy; splenectomy now rare.","refs":["rituximab"]},{"setting":"Advanced or relapsed","approach":"Rituximab with bendamustine or chlorambucil, lenalidomide-rituximab; zanubrutinib or ibrutinib for relapsed disease.","refs":["rituximab","bendamustine","chlorambucil","lenalidomide","zanubrutinib","ibrutinib"]},{"setting":"Marginal zone lymphoma: three different diseases under one name","approach":"Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT) arises at a site of chronic inflammation, most often the stomach, and is the one that can sometimes be cured with antibiotics. Splenic marginal zone lymphoma presents with a large spleen, cytopenias and circulating villous lymphocytes, and is associated with hepatitis C. Nodal marginal zone lymphoma behaves much like follicular lymphoma and is treated like it. The three share a cell of origin and very little else in the way of treatment, so the first question is which one it is.\n\nTwo tests change the plan at diagnosis. Helicobacter pylori status in gastric MALT, because eradication is the first treatment. Hepatitis C status in splenic and nodal disease, because antiviral treatment alone can produce lymphoma remission in hepatitis C-associated cases. Other site-specific associations are recorded and occasionally actionable: Chlamydia psittaci in ocular adnexal MALT, Borrelia burgdorferi in cutaneous MALT, Campylobacter jejuni in immunoproliferative small intestinal disease.","refs":["paper-esmo-marginal-zone-lymphoma-zucca-ann-oncol-2020","lymphoma-tx-h-pylori-eradication","lymphoma-tx-watch-and-wait","rituximab"],"guideline":{"version":"ESMO marginal zone lymphomas (Zucca et al.); NCCN B-Cell Lymphomas","url":"https://www.esmo.org/guidelines/esmo-clinical-practice-guidelines-haematological-malignancies"}},{"setting":"Marginal zone lymphoma that is advanced, symptomatic or has relapsed","approach":"Treatment is indicated for symptoms, organ compromise, cytopenias or rapid progression, not for the presence of disease. Rituximab alone produces responses in about half. Chemoimmunotherapy with bendamustine and rituximab is the usual choice when more is needed, and rituximab with chlorambucil has the only randomised evidence in MALT (IELSG-19: five-year event-free survival 68 per cent for the combination against 51 per cent for chlorambucil and 50 per cent for rituximab alone, with five-year overall survival about 90 per cent in each arm, so the combination delays events without changing survival).\n\nAt relapse, the BTK inhibitors are the newest class: MAGNOLIA treated relapsed or refractory marginal zone lymphoma of all subtypes with zanubrutinib and reported an objective response of 68 per cent, complete response 26 per cent and 15-month progression-free survival of 83 per cent, with fewer cardiac events than ibrutinib. Lenalidomide with rituximab is an option and marginal zone patients were included in AUGMENT. Lisocabtagene maraleucel received United States approval for relapsed or refractory marginal zone lymphoma after two or more prior lines on 4 December 2025. Local radiotherapy at 24 Gy remains the right answer for a single symptomatic site whatever the line.","refs":["rituximab","bendamustine","chlorambucil","zanubrutinib","ibrutinib","lenalidomide","lisocabtagene-maraleucel","augment","lymphoma-tx-radiotherapy","paper-magnolia-zanubrutinib-mzl-ccr-2021","paper-esmo-marginal-zone-lymphoma-zucca-ann-oncol-2020"],"guideline":{"version":"ESMO marginal zone lymphomas; NCCN B-Cell Lymphomas; IELSG-19, MAGNOLIA","url":"https://doi.org/10.1200/JCO.2016.70.6994"}}],"stateOfArt":["Gastric MALT lymphoma is the clearest example of a cancer cured by treating an infection.","Very low-dose radiotherapy controls localised disease with almost no side effects.","BTK inhibitors give durable responses in relapsed disease with zanubrutinib's approval in 2021.","Marginal zone lymphomas are united by chronic antigenic stimulation and by NF-kB activation reached through several different lesions: the API2-MALT1 fusion of t(11;18), BCL10 and MALT1 translocations, TNFAIP3 inactivation, and NOTCH2 and KLF2 mutations in the splenic form.","In the genetic taxonomy of large B-cell lymphoma, the BN2 subtype, defined by BCL6 fusions and NOTCH2 mutations, shares a pathogenesis with marginal zone lymphoma, which is one of the clearest demonstrations that the genetic classification is tracking biology rather than clustering noise.","Clonality testing earns its place here more than almost anywhere, because the differential at the small-biopsy stage is a reactive marginal zone expansion, and that question is not answered by morphology alone."],"history":[{"year":1983,"title":"Isaacson and Wright describe MALT lymphoma","refs":[]},{"year":1993,"title":"H. pylori eradication induces regression of gastric MALT lymphoma (Wotherspoon)","refs":[]},{"year":2021,"title":"Zanubrutinib approved for relapsed marginal zone lymphoma","refs":["zanubrutinib"]}],"pipeline":["zanubrutinib","lenalidomide"],"openProblems":["Transformation to diffuse large B-cell lymphoma in a minority.","No standard sequence of therapies is proven by randomised trials.","Rare sites (lung, skin, dura) are managed by extrapolation."],"parent":"non-hodgkin-lymphoma"},"route":"/cancers/marginal-zone-lymphoma/","neighbours":{"cancer":[{"id":"cutaneous-t-cell-lymphoma","kind":"cancer","name":"Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome)","route":"/cancers/cutaneous-t-cell-lymphoma/"},{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"},{"id":"malt-lymphoma","kind":"cancer","name":"Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)","route":"/cancers/malt-lymphoma/"},{"id":"follicular-lymphoma","kind":"cancer","name":"Follicular lymphoma","route":"/cancers/follicular-lymphoma/"},{"id":"gastric-malt-lymphoma","kind":"cancer","name":"Gastric MALT lymphoma","route":"/cancers/gastric-malt-lymphoma/"},{"id":"mantle-cell-lymphoma","kind":"cancer","name":"Mantle cell lymphoma","route":"/cancers/mantle-cell-lymphoma/"},{"id":"nodal-marginal-zone-lymphoma","kind":"cancer","name":"Nodal marginal zone lymphoma","route":"/cancers/nodal-marginal-zone-lymphoma/"},{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"},{"id":"ocular-adnexal-malt-lymphoma","kind":"cancer","name":"Ocular adnexal MALT lymphoma","route":"/cancers/ocular-adnexal-malt-lymphoma/"},{"id":"primary-cutaneous-marginal-zone-lymphoma","kind":"cancer","name":"Primary cutaneous marginal zone lymphoma","route":"/cancers/primary-cutaneous-marginal-zone-lymphoma/"},{"id":"splenic-marginal-zone-lymphoma","kind":"cancer","name":"Splenic marginal zone lymphoma","route":"/cancers/splenic-marginal-zone-lymphoma/"},{"id":"waldenstrom","kind":"cancer","name":"Waldenström macroglobulinaemia","route":"/cancers/waldenstrom/"}],"biomarker":[{"id":"btk-c481s","kind":"biomarker","name":"BTK resistance mutations: C481S, and L528W and T474I after the non-covalent inhibitors","route":"/biomarkers/btk-c481s/"},{"id":"cd20-expression","kind":"biomarker","name":"CD20 expression (CD20-positive)","route":"/biomarkers/cd20-expression/"},{"id":"ig-tcr-clonality","kind":"biomarker","name":"Immunoglobulin and T-cell receptor clonality","route":"/biomarkers/ig-tcr-clonality/"}],"term":[{"id":"lymphoma-decision-trial","kind":"term","name":"A clinical trial or standard treatment in lymphoma","route":"/terms/lymphoma-decision-trial/"},{"id":"cancer-related-fatigue","kind":"term","name":"Cancer-related fatigue (tiredness)","route":"/terms/cancer-related-fatigue/"},{"id":"lymphoma-tx-bispecific-step-up","kind":"term","name":"CD20 bispecific antibodies: step-up dosing, fixed duration and what it is like to take one","route":"/terms/lymphoma-tx-bispecific-step-up/"},{"id":"central-venous-access","kind":"term","name":"Central venous access (port, PICC line)","route":"/terms/central-venous-access/"},{"id":"lymphoma-living-fatigue","kind":"term","name":"Fatigue after lymphoma treatment, and why it is a symptom to report","route":"/terms/lymphoma-living-fatigue/"},{"id":"febrile-neutropenia","kind":"term","name":"Febrile neutropenia","route":"/terms/febrile-neutropenia/"},{"id":"financial-toxicity","kind":"term","name":"Financial toxicity","route":"/terms/financial-toxicity/"},{"id":"lymphoma-living-returning-to-work","kind":"term","name":"Going back to work after lymphoma, and the money in the meantime","route":"/terms/lymphoma-living-returning-to-work/"},{"id":"lymphoma-tx-h-pylori-eradication","kind":"term","name":"Helicobacter pylori eradication as cancer treatment in gastric MALT lymphoma","route":"/terms/lymphoma-tx-h-pylori-eradication/"},{"id":"lymphoma-tx-hepatitis-b-reactivation","kind":"term","name":"Hepatitis B reactivation before rituximab and other anti-CD20 antibodies","route":"/terms/lymphoma-tx-hepatitis-b-reactivation/"},{"id":"hypogammaglobulinaemia","kind":"term","name":"Hypogammaglobulinaemia and infection risk after B-cell therapies","route":"/terms/hypogammaglobulinaemia/"},{"id":"lymphoma-indolent-versus-aggressive","kind":"term","name":"Indolent and aggressive lymphoma","route":"/terms/lymphoma-indolent-versus-aggressive/"},{"id":"late-effects","kind":"term","name":"Late effects and survivorship toxicity","route":"/terms/late-effects/"},{"id":"lymphoma-living-indolent-lymphoma","kind":"term","name":"Living with an indolent lymphoma rather than being cured of one","route":"/terms/lymphoma-living-indolent-lymphoma/"},{"id":"lymphoma-living-infection-years-after","kind":"term","name":"Low antibodies and infection risk for years after anti-CD20 and bispecific antibodies","route":"/terms/lymphoma-living-infection-years-after/"},{"id":"lymphoma-bio-lymphgen","kind":"term","name":"LymphGen and the genetic clusters of large B-cell lymphoma","route":"/terms/lymphoma-bio-lymphgen/"},{"id":"m-protein-free-light-chains","kind":"term","name":"M-protein, immunofixation and serum free light chains","route":"/terms/m-protein-free-light-chains/"},{"id":"myd88-l265p","kind":"term","name":"MYD88 L265P and CXCR4 mutations","route":"/terms/myd88-l265p/"},{"id":"neutropenia","kind":"term","name":"Neutropenia","route":"/terms/neutropenia/"},{"id":"lymphoma-nodal-versus-extranodal","kind":"term","name":"Nodal and extranodal lymphoma","route":"/terms/lymphoma-nodal-versus-extranodal/"},{"id":"performance-status","kind":"term","name":"Performance status (ECOG, Karnofsky)","route":"/terms/performance-status/"},{"id":"lymphoma-tx-pod24","kind":"term","name":"POD24: progression of follicular lymphoma within two years, and why it changes the plan","route":"/terms/lymphoma-tx-pod24/"},{"id":"quality-of-life","kind":"term","name":"Quality of life","route":"/terms/quality-of-life/"},{"id":"lymphoma-tx-radiotherapy","kind":"term","name":"Radiotherapy in lymphoma: involved-site fields, 24 Gy, 4 Gy and total skin electron therapy","route":"/terms/lymphoma-tx-radiotherapy/"},{"id":"ss18-ssx-fusion","kind":"term","name":"SS18::SSX fusion (synovial sarcoma)","route":"/terms/ss18-ssx-fusion/"},{"id":"lymphoma-lugano-gastrointestinal","kind":"term","name":"Staging a lymphoma of the stomach or bowel","route":"/terms/lymphoma-lugano-gastrointestinal/"},{"id":"lymphoma-living-scanxiety-and-surveillance","kind":"term","name":"The surveillance schedule, and the evidence that routine scans do not find relapse first","route":"/terms/lymphoma-living-scanxiety-and-surveillance/"},{"id":"lymphoma-transformation","kind":"term","name":"Transformation of an indolent lymphoma","route":"/terms/lymphoma-transformation/"},{"id":"lymphoma-bio-transformation","kind":"term","name":"Transformation: when a slow lymphoma turns into a fast one","route":"/terms/lymphoma-bio-transformation/"},{"id":"lymphoma-living-vaccinations","kind":"term","name":"Vaccinations around lymphoma treatment: the ones to have first, and the ones not to have at all","route":"/terms/lymphoma-living-vaccinations/"},{"id":"lymphoma-decision-watch-and-wait","kind":"term","name":"Watch and wait in follicular lymphoma: being told you have cancer and that nobody will treat it","route":"/terms/lymphoma-decision-watch-and-wait/"},{"id":"lymphoma-tx-watch-and-wait","kind":"term","name":"Watch and wait in lymphoma: when the right treatment is none yet","route":"/terms/lymphoma-tx-watch-and-wait/"},{"id":"watchful-waiting","kind":"term","name":"Watchful waiting, and how it differs from active surveillance","route":"/terms/watchful-waiting/"},{"id":"lymphoma-tx-uk-access","kind":"term","name":"What the NHS in England funds for lymphoma, appraisal by appraisal","route":"/terms/lymphoma-tx-uk-access/"}],"roadmap":[{"id":"lymphoma-roadmap","kind":"roadmap","name":"Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting","route":"/roadmaps/lymphoma-roadmap/"}],"idea":[{"id":"lymphoma-ev-fixed-duration-chemotherapy-free-first-line","kind":"idea","name":"Fixed-duration, chemotherapy-free first-line treatment for the indolent lymphomas","route":"/ideas/lymphoma-ev-fixed-duration-chemotherapy-free-first-line/"}],"technology":[{"id":"cbt-fatigue-distress","kind":"technology","name":"Cognitive behavioural therapy for fatigue and distress","route":"/technologies/cbt-fatigue-distress/"},{"id":"cytogenetics-fish","kind":"technology","name":"Cytogenetics and FISH","route":"/technologies/cytogenetics-fish/"},{"id":"palliative-care","kind":"technology","name":"Early integrated palliative care","route":"/technologies/palliative-care/"},{"id":"exercise-during-chemotherapy","kind":"technology","name":"Exercise during chemotherapy and radiotherapy","route":"/technologies/exercise-during-chemotherapy/"},{"id":"financial-navigation","kind":"technology","name":"Financial toxicity and financial navigation","route":"/technologies/financial-navigation/"},{"id":"hypofractionated-radiotherapy","kind":"technology","name":"Hypofractionated radiotherapy","route":"/technologies/hypofractionated-radiotherapy/"},{"id":"clonality-testing","kind":"technology","name":"Immunoglobulin and T-cell receptor clonality testing","route":"/technologies/clonality-testing/"},{"id":"imrt-igrt","kind":"technology","name":"IMRT / IGRT (modern external beam)","route":"/technologies/imrt-igrt/"},{"id":"multidisciplinary-tumour-board","kind":"technology","name":"Multidisciplinary tumour boards","route":"/technologies/multidisciplinary-tumour-board/"},{"id":"flow-cytometry-mrd","kind":"technology","name":"Multiparameter flow cytometry MRD","route":"/technologies/flow-cytometry-mrd/"},{"id":"oncology-nutrition","kind":"technology","name":"Nutrition support and cachexia management","route":"/technologies/oncology-nutrition/"},{"id":"fertility-preservation","kind":"technology","name":"Oncofertility and fertility preservation","route":"/technologies/fertility-preservation/"},{"id":"peer-support-groups","kind":"technology","name":"Peer support and support groups","route":"/technologies/peer-support-groups/"},{"id":"prehabilitation","kind":"technology","name":"Prehabilitation before cancer surgery","route":"/technologies/prehabilitation/"},{"id":"psycho-oncology","kind":"technology","name":"Psycho-oncology and distress screening","route":"/technologies/psycho-oncology/"},{"id":"survivorship-care-plan","kind":"technology","name":"Survivorship care and late-effects surveillance","route":"/technologies/survivorship-care-plan/"}],"target":[{"id":"bcl10","kind":"target","name":"BCL10","route":"/targets/bcl10/"},{"id":"birc3","kind":"target","name":"BIRC3","route":"/targets/birc3/"},{"id":"cd20","kind":"target","name":"CD20","route":"/targets/cd20/"},{"id":"fas","kind":"target","name":"FAS","route":"/targets/fas/"},{"id":"klf2","kind":"target","name":"KLF2","route":"/targets/klf2/"},{"id":"malt1","kind":"target","name":"MALT1","route":"/targets/malt1/"},{"id":"myd88","kind":"target","name":"MYD88","route":"/targets/myd88/"},{"id":"notch2","kind":"target","name":"NOTCH2","route":"/targets/notch2/"},{"id":"tnfaip3","kind":"target","name":"TNFAIP3","route":"/targets/tnfaip3/"}],"drug":[{"id":"bendamustine","kind":"drug","name":"Bendamustine","route":"/drugs/bendamustine/"},{"id":"chlorambucil","kind":"drug","name":"Chlorambucil","route":"/drugs/chlorambucil/"},{"id":"ibrutinib","kind":"drug","name":"Ibrutinib","route":"/drugs/ibrutinib/"},{"id":"lenalidomide","kind":"drug","name":"Lenalidomide","route":"/drugs/lenalidomide/"},{"id":"lisocabtagene-maraleucel","kind":"drug","name":"Lisocabtagene maraleucel","route":"/drugs/lisocabtagene-maraleucel/"},{"id":"rituximab","kind":"drug","name":"Rituximab","route":"/drugs/rituximab/"},{"id":"zanubrutinib","kind":"drug","name":"Zanubrutinib","route":"/drugs/zanubrutinib/"}],"pathway":[{"id":"inflammation-nfkb","kind":"pathway","name":"Inflammation & NF-κB","route":"/pathways/inflammation-nfkb/"},{"id":"microbiome-tumour","kind":"pathway","name":"Microbiome-tumour interactions","route":"/pathways/microbiome-tumour/"},{"id":"notch","kind":"pathway","name":"Notch signalling","route":"/pathways/notch/"}],"trial":[{"id":"nct04680052","kind":"trial","name":"A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Pa","route":"/trials/nct04680052/"},{"id":"augment","kind":"trial","name":"AUGMENT","route":"/trials/augment/"},{"id":"nct06082102","kind":"trial","name":"Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma","route":"/trials/nct06082102/"},{"id":"fort","kind":"trial","name":"FoRT","route":"/trials/fort/"},{"id":"gallium","kind":"trial","name":"GALLIUM","route":"/trials/gallium/"},{"id":"ielsg-19","kind":"trial","name":"IELSG-19","route":"/trials/ielsg-19/"},{"id":"mosun-len-mzl","kind":"trial","name":"Mosunetuzumab with lenalidomide in relapsed marginal zone lymphoma","route":"/trials/mosun-len-mzl/"},{"id":"nct02793583","kind":"trial","name":"Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma","route":"/trials/nct02793583/"},{"id":"zuma-5","kind":"trial","name":"ZUMA-5","route":"/trials/zuma-5/"}],"paper":[{"id":"paper-wright-lymphgen-genetic-subtypes-dlbcl-cancer-cell-2020","kind":"paper","name":"A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications","route":"/key-papers/paper-wright-lymphgen-genetic-subtypes-dlbcl-cancer-cell-2020/"},{"id":"paper-augment-lenalidomide-rituximab-leonard-jco-2019","kind":"paper","name":"AUGMENT: lenalidomide plus rituximab versus rituximab alone in relapsed indolent lymphoma","route":"/key-papers/paper-augment-lenalidomide-rituximab-leonard-jco-2019/"},{"id":"paper-zuma-5-axi-cel-indolent-lymphoma-lancet-oncol-2022","kind":"paper","name":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial","route":"/key-papers/paper-zuma-5-axi-cel-indolent-lymphoma-lancet-oncol-2022/"},{"id":"paper-ielsg-19-chlorambucil-rituximab-malt-jco-2017","kind":"paper","name":"Final results of the IELSG-19 randomized trial of mucosa-associated lymphoid tissue lymphoma: improved event-free and progression-free survival with rituximab plus chlorambucil versus either chlorambucil or rituximab monotherapy","route":"/key-papers/paper-ielsg-19-chlorambucil-rituximab-malt-jco-2017/"},{"id":"paper-fort-long-term-follow-up-hoskin-lancet-oncol-2021","kind":"paper","name":"FoRT long-term follow-up: 4 Gy versus 24 Gy for follicular and marginal zone lymphoma","route":"/key-papers/paper-fort-long-term-follow-up-hoskin-lancet-oncol-2021/"},{"id":"paper-fort-4gy-vs-24gy-indolent-lymphoma-hoskin-lancet-oncol-2014","kind":"paper","name":"FoRT: 4 Gy versus 24 Gy radiotherapy for indolent lymphoma, a randomised phase 3 non-inferiority trial","route":"/key-papers/paper-fort-4gy-vs-24gy-indolent-lymphoma-hoskin-lancet-oncol-2014/"},{"id":"paper-magnolia-zanubrutinib-mzl-ccr-2021","kind":"paper","name":"MAGNOLIA: zanubrutinib in relapsed or refractory marginal zone lymphoma","route":"/key-papers/paper-magnolia-zanubrutinib-mzl-ccr-2021/"},{"id":"paper-esmo-marginal-zone-lymphoma-zucca-ann-oncol-2020","kind":"paper","name":"Marginal zone lymphomas: ESMO clinical practice guidelines","route":"/key-papers/paper-esmo-marginal-zone-lymphoma-zucca-ann-oncol-2020/"},{"id":"paper-wotherspoon-h-pylori-malt-lancet-1993","kind":"paper","name":"Regression of primary low-grade gastric MALT lymphoma after eradication of Helicobacter pylori","route":"/key-papers/paper-wotherspoon-h-pylori-malt-lancet-1993/"},{"id":"paper-inmind-tafasitamab-lenalidomide-rituximab-follicular-lancet-2026","kind":"paper","name":"Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial","route":"/key-papers/paper-inmind-tafasitamab-lenalidomide-rituximab-follicular-lancet-2026/"},{"id":"paper-who-2022-lymphoid-alaggio-leukemia-2022","kind":"paper","name":"WHO classification of haematolymphoid tumours, fifth edition: lymphoid neoplasms","route":"/key-papers/paper-who-2022-lymphoid-alaggio-leukemia-2022/"}],"institution":[{"id":"anthony-nolan","kind":"institution","name":"Anthony Nolan","route":"/institutions/anthony-nolan/"},{"id":"blood-cancer-uk","kind":"institution","name":"Blood Cancer UK","route":"/institutions/blood-cancer-uk/"},{"id":"lymphoma-action","kind":"institution","name":"Lymphoma Action","route":"/institutions/lymphoma-action/"}],"person":[{"id":"caron-jacobson","kind":"person","name":"Caron A. Jacobson","route":"/people/caron-jacobson/"},{"id":"john-leonard","kind":"person","name":"John P. Leonard","route":"/people/john-leonard/"}]}}